Short answer
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K current report with the SEC on April 7, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets). Asset Purchase Agreement dated April 1, 2026 between Supernus, Navitor Pharmaceuticals, Inc., and Navitor Pharmaceuticals, LLC.
SUPERNUS PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Asset Purchase Agreement dated April 1, 2026 between Supernus, Navitor Pharmaceuticals, Inc., and Navitor Pharmaceuticals, LLC
- Agreement exhibits and schedules omitted under Regulation S-K Item 601(a)(5), limiting public visibility into transaction terms
- Certain exhibit portions withheld as competitively harmful, potentially obscuring material deal economics
- Filing does not disclose purchase price, acquired assets, financing, or expected financial impact
Other items in this filing:
- Item 1.01: Entry into a Material Definitive Agreement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SUPERNUS PHARMACEUTICALS, INC. 8-K filings
Get the next SUPN 8-K as it lands
Follow SUPN for push alerts, or ask the research agent what this filing means.